Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT)

Core Viewpoint - Berger Montague PC is investigating potential securities fraud claims on behalf of investors of Altimmune, Inc. following a class action lawsuit related to the company's performance during a specified class period [1][3]. Group 1: Lawsuit Details - The class action lawsuit was filed for investors who purchased or acquired Altimmune securities between August 10, 2023, and June 25, 2025 [1][2]. - The lawsuit alleges that Altimmune's IMPACT study failed to achieve statistical significance in its primary endpoint of fibrosis reduction, which was attributed to a higher-than-expected placebo response [3]. - Following the announcement of the study results on June 26, 2025, Altimmune's stock price dropped 53%, from $7.71 per share to $3.61 per share, resulting in significant losses for investors [4]. Group 2: Company Background - Altimmune, Inc. is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland [2]. - Berger Montague has a long history in securities class action litigation, having represented individual and institutional investors for over five decades [5].